



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

21 March 2023

Cleansing Notice – Mercer Commencement Shares

As announced on 7 March 2023, the Company entered into a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC (**Investor**) on 7 March 2023 to provide funding to the Company of up to \$15,000,000 (**CSA**). Under the terms of the CSA, the Investor will be issued with 22,058,824 fully paid ordinary shares in the Company for nil consideration for entering into the CSA (at a deemed issue price of \$0.017 per share) (**Commencement Shares**). Further material terms of the CSA are set out in the Company's ASX announcement dated 7 March 2023.

The Company gives this cleansing notice (**Notice**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**). The Commencement Shares were issued without disclosure to the Investor under Part 6D.2 of the Corporations Act.

As at the date of this Notice, the Company has complied with:

- the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
- section 674 and 674A of the Corporations Act.

As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible.

For further information please visit www.imagionbiosystems.com

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Imagion Biosystems Limited

U.S. Media Contact:

Casie Ost

Casie.ost@imagionbio.com

+1-619-693-4428

Australian Media & Investor Relations:

Hannah Howlett, WE Communications

We-AUImagionBiosystems@we-worldwide.com

+61 (0) 450648064